Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ivarmacitinib for aGVHD Prevention After HLA-matched Transplantation
NCT07381114Phase 2Not yet recruiting
- Sponsor
- Institute of Hematology and Blood Diseases Hospital
- Start
- Feb 2026
- Primary completion
- Dec 2026
- Modality
- Small Molecules
01
Overview
Phase 2, open-label, single-arm trial of ivarmacitinib in Acute Graft-Versus-Host Disease (aGvHD), sponsored by Institute of Hematology and Blood Diseases Hospital. Primary endpoint: Incidence of grade II-IV acute graft-versus-host disease at 2 years. Planned start Feb 2026; status: not yet recruiting.
02
Drugs
ivarmacitinib
03
Conditions
Acute Graft-Versus-Host Disease (aGvHD)
Beyond the preview
Go deeper on NCT07381114.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07381114.